Ambu Q1 2025/26 slides: endoscopy growth offsets FX headwinds

Ambu reported Q1 FY2025/26 revenue of DKK 1,558 million, with 8.6% organic growth but only 3.2% reported growth due to a 5.4 percentage point FX headwind and tariff costs above DKK 50 million. Endoscopy Solutions was the main driver, growing 14.4% organically, while management reiterated full-year guidance for 10-13% organic growth and a 12-14% EBIT margin before special items. The stock rose 3.96% on the day, but the article also notes Q2 growth moderated to 7.3% as order-timing effects emerged.

Analysis

The market is still pricing Ambu like a cyclical industrial with FX noise, not like a category leader riding a multi-year product migration. That disconnect matters: when a platform business compounds share in a structurally expanding niche, reported growth volatility from USD/DKK can create repeated entry points, especially when the underlying mix is shifting toward higher-margin consumables and software-enabled systems. The key second-order effect is that every incremental installed base adds future razor-blade demand, so the current launch cadence should translate into a larger recurring revenue pool in 6-18 months rather than just near-term top-line beats.

The near-term risk is that the next quarter will likely look softer on a reported basis even if demand remains healthy, because order timing and tariff pass-through create a misleading deceleration narrative. That sets up a classic multiple-compression trap: investors may extrapolate a temporary growth lull into a structural slowdown just as new product penetration begins to show up in hospital purchasing cycles. In other words, the stock can stay weak in the next 4-8 weeks even if the business is improving underneath.

The more important debate is whether tariff costs are truly a margin ceiling or just a timing issue. Management’s mitigation path implies a multi-quarter bridge, but if North American production utilization improves faster than expected, the earnings power inflects before the reported margin does. Competitively, this is bad news for smaller single-use endoscopy vendors that lack a broad direct sales footprint and cannot absorb pricing, FX, and regulatory friction simultaneously; they may need to discount to defend share, which could validate Ambu’s premium positioning.

Consensus seems too focused on the 12-14% reported EBIT target and not enough on the 14-16% underlying run-rate once external drags normalize. If that gap closes over the next 2-3 quarters, the stock should re-rate on earnings power rather than on headline growth alone. The contrarian view is that this is less a turnaround story than an earnings visibility story: the setup improves materially if investors stop anchoring to quarterly noise and start discounting the installed-base flywheel.

Key Decisions for Investors

• Long AMBU on weakness over the next 2-6 weeks; use any post-print pullback driven by reported growth deceleration to build a position, targeting a 6-12 month re-rating as margin normalization becomes visible.
• Pair trade: long AMBU / short a lower-quality medtech competitor with less recurring consumables exposure and weaker direct sales reach; thesis is that Ambu’s platform economics should widen the gap as launch penetration scales.
• Buy AMBU calls or call spreads 3-6 months out to express upside from a margin relief rally; structure should capture a move if investors shift focus from FX/tariffs to underlying EBIT power.
• Avoid shorting on headline Q2 slowdown alone; the risk/reward is poor because the downside is capped by recurring portfolio growth and the upside from surprise margin recovery is asymmetric.
• Set a review trigger after the next quarterly update: if organic growth re-accelerates and gross margin holds, add aggressively; if North American production progress stalls, reduce exposure because the thesis depends on the tariff bridge closing within 2-3 quarters.